Meta-analysis of randomized, placebo-controlled clinical trials of terazosin

Peter Boyle, Claus Roehrborn, Robert J. Padley, Clem Maurath, S. Jack Zhang

Research output: Contribution to journalArticle

Abstract

Six randomized clinical trials over the last decade have compared the medical therapy terazosin with placebo for treating clinical benign prostatic hyperplasia (BPH). The findings for the 872 men in these trials provide an opportunity to investigate the heterogeneity of the ef fects seen in the individual studies as expressed by changes in symptoms ox peak urinary flow rates. A formal meta-analysis. using the approach of Hedges and Olkin (Academic Press, 1991) employed data from all t-erazosin phase III trials conducted in North America and internationally over the last decade. A pooled analysis was also undertaken on the combined data set. There were consistent effects across all six trials for terazosin and improvements in peak urinary flow rate and Boyarsky obstructive, irritative, and total symptom scores, The overall effect of terazosin was to produce an effect of 0.40 (95% CI 0.25, 0.54) compared to placebo, indicating a large and statistically significant improvement in peak urinary flow rate. Similarly large effects were noted in favor of terazosin for the Boyarsky obstructive score (0.41; 95% CI 0.27, 0.56) and the Boyarsky irritative score (0.33; 95% CI 0.19, 0.48). This meta-analysis confirms that terazosin is an effective therapeutic agent in the treatment of clinical BPH and that the therapeut ic value of terazosin was well established from the results of early studies. In light of advancing knowledge of BPH, it may be worthwhile to further invest igate the effect of terazosin in terms of different BPH symptom subsets and quality-of-life domains.

Original languageEnglish (US)
Pages (from-to)223
Number of pages1
JournalBritish Journal of Urology
Volume80
Issue numberSUPPL. 2
StatePublished - 1997

Fingerprint

Terazosin
Meta-Analysis
Randomized Controlled Trials
Placebos
Prostatic Hyperplasia
North America

ASJC Scopus subject areas

  • Urology

Cite this

Boyle, P., Roehrborn, C., Padley, R. J., Maurath, C., & Jack Zhang, S. (1997). Meta-analysis of randomized, placebo-controlled clinical trials of terazosin. British Journal of Urology, 80(SUPPL. 2), 223.

Meta-analysis of randomized, placebo-controlled clinical trials of terazosin. / Boyle, Peter; Roehrborn, Claus; Padley, Robert J.; Maurath, Clem; Jack Zhang, S.

In: British Journal of Urology, Vol. 80, No. SUPPL. 2, 1997, p. 223.

Research output: Contribution to journalArticle

Boyle, P, Roehrborn, C, Padley, RJ, Maurath, C & Jack Zhang, S 1997, 'Meta-analysis of randomized, placebo-controlled clinical trials of terazosin', British Journal of Urology, vol. 80, no. SUPPL. 2, pp. 223.
Boyle, Peter ; Roehrborn, Claus ; Padley, Robert J. ; Maurath, Clem ; Jack Zhang, S. / Meta-analysis of randomized, placebo-controlled clinical trials of terazosin. In: British Journal of Urology. 1997 ; Vol. 80, No. SUPPL. 2. pp. 223.
@article{f0e3b5cbbcc349e1a91a9c27ba1fd297,
title = "Meta-analysis of randomized, placebo-controlled clinical trials of terazosin",
abstract = "Six randomized clinical trials over the last decade have compared the medical therapy terazosin with placebo for treating clinical benign prostatic hyperplasia (BPH). The findings for the 872 men in these trials provide an opportunity to investigate the heterogeneity of the ef fects seen in the individual studies as expressed by changes in symptoms ox peak urinary flow rates. A formal meta-analysis. using the approach of Hedges and Olkin (Academic Press, 1991) employed data from all t-erazosin phase III trials conducted in North America and internationally over the last decade. A pooled analysis was also undertaken on the combined data set. There were consistent effects across all six trials for terazosin and improvements in peak urinary flow rate and Boyarsky obstructive, irritative, and total symptom scores, The overall effect of terazosin was to produce an effect of 0.40 (95{\%} CI 0.25, 0.54) compared to placebo, indicating a large and statistically significant improvement in peak urinary flow rate. Similarly large effects were noted in favor of terazosin for the Boyarsky obstructive score (0.41; 95{\%} CI 0.27, 0.56) and the Boyarsky irritative score (0.33; 95{\%} CI 0.19, 0.48). This meta-analysis confirms that terazosin is an effective therapeutic agent in the treatment of clinical BPH and that the therapeut ic value of terazosin was well established from the results of early studies. In light of advancing knowledge of BPH, it may be worthwhile to further invest igate the effect of terazosin in terms of different BPH symptom subsets and quality-of-life domains.",
author = "Peter Boyle and Claus Roehrborn and Padley, {Robert J.} and Clem Maurath and {Jack Zhang}, S.",
year = "1997",
language = "English (US)",
volume = "80",
pages = "223",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Meta-analysis of randomized, placebo-controlled clinical trials of terazosin

AU - Boyle, Peter

AU - Roehrborn, Claus

AU - Padley, Robert J.

AU - Maurath, Clem

AU - Jack Zhang, S.

PY - 1997

Y1 - 1997

N2 - Six randomized clinical trials over the last decade have compared the medical therapy terazosin with placebo for treating clinical benign prostatic hyperplasia (BPH). The findings for the 872 men in these trials provide an opportunity to investigate the heterogeneity of the ef fects seen in the individual studies as expressed by changes in symptoms ox peak urinary flow rates. A formal meta-analysis. using the approach of Hedges and Olkin (Academic Press, 1991) employed data from all t-erazosin phase III trials conducted in North America and internationally over the last decade. A pooled analysis was also undertaken on the combined data set. There were consistent effects across all six trials for terazosin and improvements in peak urinary flow rate and Boyarsky obstructive, irritative, and total symptom scores, The overall effect of terazosin was to produce an effect of 0.40 (95% CI 0.25, 0.54) compared to placebo, indicating a large and statistically significant improvement in peak urinary flow rate. Similarly large effects were noted in favor of terazosin for the Boyarsky obstructive score (0.41; 95% CI 0.27, 0.56) and the Boyarsky irritative score (0.33; 95% CI 0.19, 0.48). This meta-analysis confirms that terazosin is an effective therapeutic agent in the treatment of clinical BPH and that the therapeut ic value of terazosin was well established from the results of early studies. In light of advancing knowledge of BPH, it may be worthwhile to further invest igate the effect of terazosin in terms of different BPH symptom subsets and quality-of-life domains.

AB - Six randomized clinical trials over the last decade have compared the medical therapy terazosin with placebo for treating clinical benign prostatic hyperplasia (BPH). The findings for the 872 men in these trials provide an opportunity to investigate the heterogeneity of the ef fects seen in the individual studies as expressed by changes in symptoms ox peak urinary flow rates. A formal meta-analysis. using the approach of Hedges and Olkin (Academic Press, 1991) employed data from all t-erazosin phase III trials conducted in North America and internationally over the last decade. A pooled analysis was also undertaken on the combined data set. There were consistent effects across all six trials for terazosin and improvements in peak urinary flow rate and Boyarsky obstructive, irritative, and total symptom scores, The overall effect of terazosin was to produce an effect of 0.40 (95% CI 0.25, 0.54) compared to placebo, indicating a large and statistically significant improvement in peak urinary flow rate. Similarly large effects were noted in favor of terazosin for the Boyarsky obstructive score (0.41; 95% CI 0.27, 0.56) and the Boyarsky irritative score (0.33; 95% CI 0.19, 0.48). This meta-analysis confirms that terazosin is an effective therapeutic agent in the treatment of clinical BPH and that the therapeut ic value of terazosin was well established from the results of early studies. In light of advancing knowledge of BPH, it may be worthwhile to further invest igate the effect of terazosin in terms of different BPH symptom subsets and quality-of-life domains.

UR - http://www.scopus.com/inward/record.url?scp=33749313630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749313630&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 223

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - SUPPL. 2

ER -